ImmunoCellular Therapeutics is a clinical-stage company focused on the development of immune-based therapies for treating brain and other cancers. The company is conducting a Phase II trial of its lead product candidate ICT-107, which is a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. The company’s pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. For more information, visit the company’s Web site at www.imuc.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: